Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm county, Sweden

Clinical Infectious Diseases

Volumn 52, Issue 10, 2011, Pages 1203-1211

  Örtqvist, Åke ^a,b   Berggren, Ingela ^a,b   Insulander, Mona ^a   De Jong, Birgitta ^a,c   Svenungsson, Bo ^a,b  

^a Smittskydd Stockholm ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

2009 H1N1 INFLUENZA; ADOLESCENT; AGED; ARTICLE; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HOSPITAL ADMISSION; HUMAN; IMMUNOCOMPROMISED PATIENT; INFANT; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SWEDEN; TREATMENT DURATION; TREATMENT FAILURE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SWEDEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955406980     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir182     Document Type: Article

References (33)

1. http://www.ema.europa.eu/influenza/home.htm. Accessed on 22 March 2011.
2. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35.
3. Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13.
4. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375:41-8.
5. Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010; 303:37-46.
6. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-5.
7. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649.
8. Carmona A, Omenaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months of age. Vaccine 2010; 28:5837-44.
9. Wichmann O, Stocker P, Poggensee G, et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 2010; 15:19561.
10. Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Vaccine effectiveness in pandemic influenza-primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A(H1N1)v vaccine. Health Technol Assess 2010; 14:313-46.
11. Van Buynder PG, Dhaliwal JK, Van Buynder JL, et al. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respi Viruses 2010; 4:171-8.
12. Puig-Barbera J, Arnedo-Pena A, Pardo-Serrano F, et al. Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study. Vaccine 2010; 28:7460-7.
13. Valenciano M, Kissling E, Cohen J-M, et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010. Results of In- fluenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med 2010; 8:e1000388.
14. Hardelid P, Fleming DM, McMenamin J, et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing influenza A (H1N1)2009 infection in England and Scotland 2009-2010. Euro Surveill 2010; 16:19763.
15. Wu J, Xu F, Lu L, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. New Engl J Med 2010; 363:2416-23.
16. http://www.socialstyrelsen.se/publikationer2009/2009-10-118/Sidor/ default.aspx. Accessed on 22 March 2011.
17. http://www.socialstyrelsen.se/publikationer2009/2009-130-14. Accessed on 22 March 2011.
18. Rolfhamre P, Jansson A, ArnebornM, Ekdahl K. SmiNet-2: description of an Internet-based surveillance system for communicable diseases in Sweden. Euro Surveill 2006; 11:103-7.
19. Tiveljung-Lindell A, Rotzen-Ostlund M, Gupta S, et al. Development and implementation of a molecular diagnostic platform for daily rapid detection of 15 respiratory viruses. J Med Virol 2009; 81:167-75.
20. http://www.ecdc.europa.eu/en/publications/Publications/0912-TED- Protocol-for-Cluster-Investigations-to-Measure-Influenza-Vaccine- Effectiveness.pdf. Accessed on 22 March 2011.
21. Langley JM, Reich D, Aggarwal N, et al. Immunogenicity safety of an H1N1 2009 pandemic influenza vaccine formulated with and without AS03 adjuvant in children aged 6 months to less than 9 years [abstract]. Presented at: Options for the Control of Influenza VII, Hong Kong, September 3-7.
22. Swedish Center for Infectious Disease Control. Epidemiologic yearly report, 2009, p.7. Available at: http://www.smittskyddsinstitutet.se/upload/ Publikationer/epi-arsrapport-2009.pdf. Accessed on 22March 2011.
23. Wu JT, Ma ES, Lee CK, et al. The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis 2010; 51:1184-91.
24. Bandaranayake D, Huang QS, Bissielo A, et al. Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemic. PLoS One 2010; 5:e13211.
25. Gilbert GL, Cretikos MA, Hueston L, Doukas G, O'Toole B, Dwyer DE. Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter. PLoS One 2010; 5:e12562.
26. Baker M, Kelly H, Wilson N. Pandemic H1N1 influenza lessons from the southern hemisphere. Euro Surveill 2009; 14:19370.
27. Jain S, Kamimoto L, Bramley AM, et al. Hospitalised patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935-44.
28. Belongia EA, Irving SA, Waring SC, et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA 2010; 304:1091-8.
29. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-19.
30. Fielding JE, Higgins N, Gregory JE, et al. Pandemic H1N1 influenza surveillance in Victoria, Australia, April-September, 2009. Euro Surveill 2009; 14:19368.
31. Gómez J, Munayco CV, Arrasco JC, et al. Pandemic influenza in a southern hemisphere setting: the experience in Peru from May to September, 2009. Euro Surveill 2009; 14:19371.
32. Oliveira WK, Hage EC, Penna GO, et al. Pandemic H1N1 influenza in Brazil: analysis of the first 34,506 notified cases of influenza-like illness with severe acute respiratory infection (SARI). Euro Surveill 2009; 14:19362.
33. Archer BN, Cohen C, Naidoo D, et al. Interim report on pandemic H1N1 influenza virus infections in South Africa, April to October 2009: epidemiology and factors associated with fatal cases. Euro Surveill 2009; 14:19369.